Tiziana life sciences completes enrollment of the first patient cohort for its intermediate-size patient population expanded access program to evaluate foralumab in non-active secondary multiple sclerosis patients

New york, nov. 02, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced completion of enrollment of the first patient cohort (n=4) in its intermediate-size patient population expanded access program to evaluate foralumab in non-active secondary progressive multiple sclerosis (spms) patients has quickly been completed, following the start of enrollment announced last week.
TLSA Ratings Summary
TLSA Quant Ranking